Anna Clara Monti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Clara Monti has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Masanobu Taniguchi
Waseda University
2 shared publications - Daniel Guimarães Tiezzi
Universidade de São Paulo
1 shared publication - Domenico Scalera
University of Sannio
1 shared publication - Elvezio Ronchetti
University of Geneva
1 shared publication - Fabiana de Oliveira Buono
Laboratory for Translational Data Science, Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, Brazil
1 shared publication - Fumiya Akashi
Waseda University
1 shared publication
Latest Publications
- Open Access
- 6 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11809
The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy
The cHER2+ breast cancer subtype is characterized by the overexpression of the HER2 oncoprotein based on immunohistochemistry (IHC)/or by ERBB2 gene amplification using in situ hybridization (ISH) techniques. Targeted therapies are significantly changing cancer treatment outcomes. However, not all patients benefit from it due to misclassification or intrinsic mechanisms of resistance. Identifying predictive factors of response to therapy is thus crucial for optimizing treatment protocol. In addition, with the development of effective antibody–drug conjugates for targeting HER2-low subtypes, enhancing the HER2 molecular classification is crucial. In this study, a comprehensive analysis of publicly available datasets (TCGA, METABRIC, I-SPY, NOAH and CHER-LOB trials) has been considered. We present a metagene expression score (HER2MtGx 31-gene assay) based on the most informative genes associated with each molecular profile. HER2MtGx scores represent three linear subspaces associated with the HER2, Luminal and Basal-like profiles (STAT). In the METABRIC cohort, the scores are useful to discriminate against the HER2-enriched phenotype and this classification is significantly associated with long-term survival in cHER2+ patients (HR = 1.76; 95%CI = 1.09–2.86). In terms of response to neoadjuvant chemo/target therapy including I-SPY, NOAH, and CHER-LOB trials, the metagene scores are associated with the pathological response to therapy (OR = 2.26; 95%CI = 1.74–2.98). The HER2MtGx assay is a reliable tool for selecting patients for HER2-targeted therapy.
- 6 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11809
Open AccessThe HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy
The cHER2+ breast cancer subtype is characterized by the overexpression of the HER2 oncoprotein based on immunohistochemistry (IHC)/or by ERBB2 gene amplification using in situ hybridization (ISH) techniques. Targeted therapies are significantly changing cancer treatment outcomes. However, not all patients benefit from it due to misclassification or intrinsic mechanisms of resistance. Identifying predictive factors of response to therapy is thus crucial for optimizing treatment protocol. In addition, with the development of effective antibody–drug conjugates for targeting HER2-low subtypes, enhancing the HER2 molecular classification is crucial. In this study, a comprehensive analysis of publicly available datasets (TCGA, METABRIC, I-SPY, NOAH and CHER-LOB trials) has been considered. We present a metagene expression score (HER2MtGx 31-gene assay) based on the most informative genes associated with each molecular profile. HER2MtGx scores represent three linear subspaces associated with the HER2, Luminal and Basal-like profiles (STAT). In the METABRIC cohort, the scores are useful to discriminate against the HER2-enriched phenotype and this classification is significantly associated with long-term survival in cHER2+ patients (HR = 1.76; 95%CI = 1.09–2.86). In terms of response to neoadjuvant chemo/target therapy including I-SPY, NOAH, and CHER-LOB trials, the metagene scores are associated with the pathological response to therapy (OR = 2.26; 95%CI = 1.74–2.98). The HER2MtGx assay is a reliable tool for selecting patients for HER2-targeted therapy.
- Open Access
- 20 June 2024
- Published by College of Management, University of Information Technology and Management in Rzeszów in Financial Internet Quarterly
- Vol. 20 (2) , 1-14
MODELING FINANCIAL RISK ATTITUDE
This paper studies the relationship between risk propensity, education and financial literacy. Theresults of the empirical investigation confirm the importance of the key explanatory variables ofeducation and financial competence. Since they are both included in the model, the differentroles of each are singled out. In particular, while education turns out to be a factor contributingto raising risk tolerance, financial literacy tends to reduce risk propensity. Risk attitude is evaluated by self-reported assessment and modeled through cumulative logit models. In order to handle anomalous data, M estimators with a bounded influence function are considered.
- 20 June 2024
- Published by College of Management, University of Information Technology and Management in Rzeszów in Financial Internet Quarterly
- Vol. 20 (2) , 1-14
Open AccessMODELING FINANCIAL RISK ATTITUDE
This paper studies the relationship between risk propensity, education and financial literacy. Theresults of the empirical investigation confirm the importance of the key explanatory variables ofeducation and financial competence. Since they are both included in the model, the differentroles of each are singled out. In particular, while education turns out to be a factor contributingto raising risk tolerance, financial literacy tends to reduce risk propensity. Risk attitude is evaluated by self-reported assessment and modeled through cumulative logit models. In order to handle anomalous data, M estimators with a bounded influence function are considered.
- 1 January 2018
- Published by Statistica Sinica (Institute of Statistical Science) in Statistica Sinica
- Vol. 28 (3) , 1437-1458
Adjustments for a class of tests under nonstandard conditions
- 1 January 2018
- Published by Statistica Sinica (Institute of Statistical Science) in Statistica Sinica
- Vol. 28 (3) , 1437-1458
Adjustments for a class of tests under nonstandard conditions
- 31 July 2017
- Published by Springer Nature in Sankhya A
- Vol. 80 (1) , 121-137
A New Look at Portmanteau Tests
- 31 July 2017
- Published by Springer Nature in Sankhya A
- Vol. 80 (1) , 121-137
A New Look at Portmanteau Tests
- 8 July 2017
- Published by Springer Nature in Statistical Methods & Applications
- Vol. 27 (1) , 25-44
Testing for sub-models of the skew t-distribution
- 8 July 2017
- Published by Springer Nature in Statistical Methods & Applications
- Vol. 27 (1) , 25-44
Testing for sub-models of the skew t-distribution
- Open Access
- 1 June 1993
- Published by JSTOR in Biometrika
- Vol. 80 (2) , 329
On the Relationship Between Empirical Likelihood and Empirical Saddlepoint Approximation for Multivariate M-Estimators
- 1 June 1993
- Published by JSTOR in Biometrika
- Vol. 80 (2) , 329
Open AccessOn the Relationship Between Empirical Likelihood and Empirical Saddlepoint Approximation for Multivariate M-Estimators